{"id":44481,"date":"2022-12-01T07:18:49","date_gmt":"2022-12-01T07:18:49","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=44481"},"modified":"2022-12-15T21:33:03","modified_gmt":"2022-12-15T21:33:03","slug":"bhiva-2022-art-guidelines-online-with-non-technical-summary","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/44481","title":{"rendered":"BHIVA 2022 ART guidelines: online with non-technical summary"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong><span lang=\"EN-US\">The 2022 antiretroviral therapy (ART) guidelines are now online, together with a non-technical summary. [1, 2]<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">They provide guidance on best clinical practice for ART and management of adults living with HIV. <\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The scope includes: <\/span><\/p>\n<\/div>\n<div>\n<ul>\n<li class=\"HTBBODYtext\"><span lang=\"EN-US\">Starting ART in those previously na\u00efve to therapy.<\/span><\/li>\n<li class=\"HTBBODYtext\">Support for people already on ART.<\/li>\n<li class=\"HTBBODYtext\">Management of viral rebound.<\/li>\n<li class=\"HTBBODYtext\">Changing ART for tolerability and\/or toxicity issues.<\/li>\n<li class=\"HTBBODYtext\">Recommendations for specific populations where other factors are important.<\/li>\n<\/ul>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The guidelines are written for healthcare professionals directly involved with and responsible for the care of adults living with HIV, community advocates responsible for promoting the best interests and care of adults living with HIV, and people living with HIV for whom a non-technical summary is also available, if preferred. <\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">They should be read in conjunction with other published BHIVA guidelines.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">BHIVA also publishes the consultation comments received to the first draft of these guidelines and the responses from the guideline panel. [3]<\/p>\n<\/div>\n<div>\n<p class=\"HTBreferences\"><span lang=\"EN-US\">References<\/span><\/p>\n<\/div>\n<div>\n<ol>\n<li class=\"HTBreferences\"><span lang=\"EN-US\">BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022<br \/>\n<\/span><a href=\"https:\/\/www.bhiva.org\/HIV-1-treatment-guidelines\">https:\/\/www.bhiva.org\/HIV-1-treatment-guidelines<\/a><\/li>\n<li class=\"HTBreferences\">Non-technical community summaries.<br \/>\n<a href=\"https:\/\/www.bhiva.org\/HIV-1-treatment-guidelines\">https:\/\/www.bhiva.org\/HIV-1-treatment-guidelines<\/a><\/li>\n<li class=\"HTBreferences\">BHIVA. Consultation comments on the initial draft and panel responses.<br \/>\n<a href=\"https:\/\/www.bhiva.org\/file\/635139fadbc5e\/consultation-comments.pdf\">https:\/\/www.bhiva.org\/file\/635139fadbc5e\/consultation-comments.pdf<\/a> (PDF)<\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base The 2022 antiretroviral therapy (ART) guidelines are now online, together with a non-technical summary. [1, 2] They provide guidance on best clinical practice for ART and management of adults living with HIV. The scope includes: Starting &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":["post-44481","post","type-post","status-publish","format-standard","hentry","category-guidelines"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=44481"}],"version-history":[{"count":2,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44481\/revisions"}],"predecessor-version":[{"id":44483,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44481\/revisions\/44483"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=44481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=44481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=44481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}